Progression-free status at 24 months was a strong prognostic marker for overall survival at the patient level in HPV-positive oropharyngeal cancer and future trial-level analysis is now warranted. The adoption of this endpoint has the potential to accelerate therapeutic development by enabling earlier evaluation of treatment activity, thereby facilitating the timely introduction of novel therapies to this patient population before…
[Articles] Evaluation of progression-free status at 24 months as a surrogate endpoint for overall survival in patients with human papillomavirus-positive oropharyngeal cancer: a retrospective cohort study
The Lancet Oncology | | Caineng Cao, Eric J Sherman, Nadeem Riaz, Sean M McBride, Yao Yu, Achraf Shamseddine, Winston Wong, Lara A Dunn, Alan L Ho, Richard J Wong, Nancy Y Lee
Topics: blood-cancer, head-neck-cancer, clinical-trials, research